Evidence map›Paper›PMID 33431996›Full record

ArticleScientific reports2021

Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study.

Teruhide Koyama, Nagato Kuriyama, Yosuke Suzuki, Satoshi Saito, Ryota Tanaka, Motoshi Iwao, Megumu Tanaka, Takakuni Maki, Hiroki Itoh, Masafumi Ihara and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Emerging biomarkers for the detection of cardiovascular diseases.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Observational
  18. Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Teruhide KoyamaDepartment of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. tkoyama@koto.kpu-m.ac.jp.
Nagato KuriyamaDepartment of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yosuke SuzukiDepartment of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.
Satoshi SaitoDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
Ryota TanakaDepartment of Clinical Pharmacy, Oita University Hospital, Oita, Japan.
Motoshi IwaoDepartment of Clinical Pharmacy, Oita University Hospital, Oita, Japan.
Megumu TanakaDepartment of Cardiovascular Research, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
Takakuni MakiDepartment of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroki ItohDepartment of Clinical Pharmacy, Oita University Hospital, Oita, Japan.
Masafumi IharaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
Takayuki ShindoDepartment of Cardiovascular Research, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
Ritei UeharaDepartment of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Oita University Hospital · JPKyoto Prefectural University of Medicine · JPNational Cerebral and Cardiovascular Center · JPShinshu University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the potential of mid-regional pro-adrenomedullin (MR-proADM) for use as a novel biomarker for arterial stiffness as the criterion for vascular failure and cardiometabolic disease (obesity, hypertension, dyslipidemia, diabetes, and metabolic syndrome) compared with high-sensitivity C-reactive protein (hsCRP). Overall, 2169 individuals (702 men and 1467 women) were enrolled. Multiple regression analysis was performed to assess the association of MR-proADM and hsCRP with brachial-ankle pulse wave velocity (baPWV), adjusting for other variables. The diagnostic performance (accuracy) of MR-proADM with regard to the index of vascular failure was tested with the help of receiver operating characteristic curve analysis in the models. MR-proADM was significantly higher in participants with vascular failure, as defined by baPWV and/or its risk factors (obesity, hypertension, dyslipidemia, diabetes, and metabolic syndrome), than in control groups. Independent of cardiovascular risk factors (age, drinking, smoking, body mass index, systolic blood pressure, lipid and glycol metabolism), MR-proADM was significantly associated with baPWV, and MR-proADM showed higher areas under the curve of baPWV than hsCRP showed. MR-proADM is more suitable for the diagnosis of higher arterial stiffness as the criterion for vascular failure than hsCRP. Because vascular assessment is important to mitigate the most significant modifiable cardiovascular risk factors, MR-proADM may be useful as a novel biomarker on routine blood examination.

Indexed as

Vascular StiffnessAdrenomedullinAdultAgedBiomarkersCross-Sectional StudiesFemaleHumansMaleMiddle AgedRegression AnalysisRisk FactorsVascular DiseasesAdrenomedullinBiomarkers

Identifiers

PMID33431996
PMCPMC7801498
OpenAlexW3119376900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.